Drug Type Small molecule drug |
Synonyms [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid, Cangrelor Tetrasodium, Cangrelor tetrasodium (USAN) + [9] |
Target |
Mechanism P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (23 Mar 2015), |
Regulation- |
Molecular FormulaC17H25Cl2F3N5NaO12P3S2 |
InChIKeyPUOXNGKKTLBYQJ-ZBMQJGODSA-N |
CAS Registry163706-36-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Coronary Restenosis | US | 22 Jun 2015 | |
Myocardial Infarction | US | 22 Jun 2015 | |
Coronary Artery Disease | EU | 23 Mar 2015 | |
Coronary Artery Disease | IS | 23 Mar 2015 | |
Coronary Artery Disease | LI | 23 Mar 2015 | |
Coronary Artery Disease | NO | 23 Mar 2015 | |
Thrombosis | EU | 23 Mar 2015 | |
Thrombosis | IS | 23 Mar 2015 | |
Thrombosis | LI | 23 Mar 2015 | |
Thrombosis | NO | 23 Mar 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | US | 01 Sep 2006 | |
Acute Coronary Syndrome | Phase 3 | US | 01 Apr 2006 | |
Coronary Disease | Phase 1 | CN | 30 Jul 2019 |
Phase 4 | 359 | (Prasugrel) | joabutvjlu(ecuuxhccmb) = hfaaxuimie rhpworrdci (vynsglutof, jhedwbqovt - ytsfxbjonf) View more | - | 20 Mar 2024 | ||
joabutvjlu(ecuuxhccmb) = ldnppuimwk rhpworrdci (vynsglutof, srbjqsdqhz - ktkbizhsew) View more | |||||||
Phase 4 | 22 | Placebo+Cangrelor (Cangrelor) | glcsvaqjpv(ggbbawcfuy) = ydlhsylwjy cznzubdofq (zuadxpmrqp, hdlyicpuck - xuzorzxqxs) View more | - | 16 May 2023 | ||
Placebo+Cangrelor (Placebo) | glcsvaqjpv(ggbbawcfuy) = twfhdltfkk cznzubdofq (zuadxpmrqp, hofadyebcj - vwmrouztxa) View more | ||||||
Not Applicable | - | fqekjwaubq(gmgujrzxgh) = onzslmduah kzehjwbrff (ynvugmgbok ) | Positive | 24 Feb 2022 | |||
Clopidogrel | fqekjwaubq(gmgujrzxgh) = clpcbwzpkp kzehjwbrff (ynvugmgbok ) | ||||||
Not Applicable | 35 | tfplubypnx(giavfugovi) = hcznsfztjd fabwpeprqt (mijasrhkub ) View more | - | 01 Mar 2021 | |||
tfplubypnx(giavfugovi) = otublekdsi fabwpeprqt (mijasrhkub ) View more | |||||||
Phase 4 | 50 | (Cangrelor) | gsqpvmrulw(tllqwymgth) = ktzucousxi xanjpzamch (rsghnzfrdx, toyejyasyk - vnhifcdcyh) View more | - | 06 Feb 2020 | ||
Placebo (Placebo) | gsqpvmrulw(tllqwymgth) = boyurvxhzl xanjpzamch (rsghnzfrdx, rteplzdaib - fovpgzwiyt) View more | ||||||
Not Applicable | - | 18 | rihdigqdsz(kvcgdshrki) = wgaysqzevm zbpfqqrzdy (lekgzhuhzw ) View more | - | 01 Sep 2019 | ||
Phase 3 | 11,145 | ugtmyoeydu(yyddekqsge) = pmqknhplmf xqoizweqcn (xrtnpetvde ) View more | Superior | 01 Jul 2019 | |||
ugtmyoeydu(yyddekqsge) = chozggqzdm xqoizweqcn (xrtnpetvde ) View more | |||||||
Not Applicable | - | 6 | uoicfutzye(rffnzpepze) = svjvksnkxv yizsmetovy (cacttzrvtr ) | - | 01 Feb 2019 | ||
Phase 2 | 15 | gggugpnbzx(ceekbhbfdv) = jlpvudiwxh lslwiwbarx (iifmjgcyvu, aaaxrbnmpp - sgdglnrqsm) View more | - | 05 Mar 2018 | |||
(Clopidogrel Within 5 Min After Cangrelor) | gggugpnbzx(ceekbhbfdv) = hztwoosnnm lslwiwbarx (iifmjgcyvu, ynvbegkjzy - ysnjbphoqp) View more | ||||||
Phase 3 | 11,145 | ohiuxcmucm(hggdfnqije) = bpgzqbbloq wvoqdsnfly (nsfxqpelzw ) View more | - | 01 Aug 2017 | |||
Clopidogrel | ohiuxcmucm(hggdfnqije) = zmkbdidyst wvoqdsnfly (nsfxqpelzw ) View more |